Literature DB >> 16502396

Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C.

Arun J Sanyal1, Colin Banas, Carol Sargeant, Velimir A Luketic, Richard K Sterling, Richard T Stravitz, Mitchell L Shiffman, Douglas Heuman, Adrian Coterrell, Robert A Fisher, Melissa J Contos, Alan S Mills.   

Abstract

The objective of this study was to prospectively define outcomes of cirrhosis due to nonalcoholic steatohepatitis (NASH) and compare them with those associated with hepatitis C virus (HCV) infection. We compared 152 patients with cirrhosis due to NASH with 150 matched patients with cirrhosis due to HCV. Over 10 years, 29/152 patients with cirrhosis due to NASH died compared with 44/150 patients with HCV (P < .04). This was mainly due to the lower mortality rate in patients with Child class A cirrhosis due to NASH versus HCV (3/74 vs. 15/75; P < .004). There were no significant across-group differences in mortality in patients with Child class B or C cirrhosis. Sepsis was the most common cause of death in both groups; patients with NASH had a higher cardiac mortality (8/152 vs. 1/150; P < .03). Patients with Child class A cirrhosis due to NASH also had a significantly lower risk of decompensation, defined by a 2-point increase in Child-Turcotte-Pugh score (P < .007). Cirrhosis due to NASH was associated with a lower rate of development of ascites (14/101 vs. 40/97 patients at risk; P < .006). NASH also had a significantly lower risk of development of hepatocellular carcinoma (10/149 vs. 25/147 patients at risk; P < .01). In conclusion, compensated cirrhosis due to NASH is associated with a lower mortality rate compared with that due to HCV. It is also associated with a lower rate of development of ascites, hyperbilirubinemia, and hepatocellular carcinoma. However, cardiovascular mortality is greater in patients with NASH.

Entities:  

Mesh:

Year:  2006        PMID: 16502396     DOI: 10.1002/hep.21103

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  135 in total

1.  Atherogenic dyslipidemia and cardiovascular risk in children with nonalcoholic fatty liver disease.

Authors:  Naim Alkhouri; Christine Carter-Kent; Michael Elias; Ariel E Feldstein
Journal:  Clin Lipidol       Date:  2011-06-01

Review 2.  Quantitative Assessment of Liver Fat with Magnetic Resonance Imaging and Spectroscopy.

Authors:  Scott B Reeder; Irene Cruite; Gavin Hamilton; Claude B Sirlin
Journal:  J Magn Reson Imaging       Date:  2011-09-16       Impact factor: 4.813

Review 3.  Cryptogenic cirrhosis: what are we missing?

Authors:  Stephen Caldwell
Journal:  Curr Gastroenterol Rep       Date:  2010-02

Review 4.  Quantification of liver fat with magnetic resonance imaging.

Authors:  Scott B Reeder; Claude B Sirlin
Journal:  Magn Reson Imaging Clin N Am       Date:  2010-08       Impact factor: 2.266

5.  Diagnosis and prognostic significance of minimal hepatic encephalopathy in patients with cirrhosis of liver.

Authors:  Radha K Dhiman; Roshan Kurmi; Kiran K Thumburu; Sunil H Venkataramarao; Ritesh Agarwal; Ajay Duseja; Yogesh Chawla
Journal:  Dig Dis Sci       Date:  2010-05-28       Impact factor: 3.199

Review 6.  Current and Future Burden of Chronic Nonmalignant Liver Disease.

Authors:  Prowpanga Udompap; Donghee Kim; W Ray Kim
Journal:  Clin Gastroenterol Hepatol       Date:  2015-08-17       Impact factor: 11.382

7.  Portal lymphadenopathy predicts non-alcoholic steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease.

Authors:  Saleh Daher; Namma Lev Cohen; Muhammad Massarwa; Mahmud Mahamid; Mira Nasser; Wadi Hazou; Rani Oren; Rifaat Safadi; Tawfik Khoury
Journal:  PLoS One       Date:  2018-11-30       Impact factor: 3.240

8.  Motion-robust, high-SNR liver fat quantification using a 2D sequential acquisition with a variable flip angle approach.

Authors:  Ruiyang Zhao; Yuxin Zhang; Xiaoke Wang; Timothy J Colgan; Jennifer L Rehm; Scott B Reeder; Kevin M Johnson; Diego Hernando
Journal:  Magn Reson Med       Date:  2020-04-03       Impact factor: 4.668

9.  Liver fat volume fraction quantification with fat and water T1 and T 2* estimation and accounting for NMR multiple components in patients with chronic liver disease at 1.5 and 3.0 T.

Authors:  Benjamin Leporq; Hélène Ratiney; Frank Pilleul; Olivier Beuf
Journal:  Eur Radiol       Date:  2013-04-16       Impact factor: 5.315

10.  Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis.

Authors:  Etsuko Hashimoto; Satoru Yatsuji; Maki Tobari; Makiko Taniai; Nobuyuki Torii; Katsutoshi Tokushige; Keiko Shiratori
Journal:  J Gastroenterol       Date:  2009-01-16       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.